SCHEMBL6886816

SCHEMBL6886816

COc1ccc2c(c1)-c1nc(N/C=N\O)sc1CC2

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 17/20 0.60
TP53 P04637 7/20 0.60
RXFP1 Q9HBX9 1/20 0.59
ALDH1A1 P00352 9/20 0.59
KDM4E B2RXH2 7/20 0.59
MPI P34949 2/20 0.59
MEN1 O00255 3/20 0.57
KMT2A Q03164 3/20 0.57
HPGD P15428 3/20 0.57
CYP1A2 P05177 2/20 0.57
CYP3A4 P08684 2/20 0.57
CYP2C9 P11712 2/20 0.57
CYP2C19 P33261 2/20 0.57
NPSR1 Q6W5P4 2/20 0.57
LMNA P02545 1/20 0.57
CYP2D6 P10635 1/20 0.57
PKM P14618 1/20 0.57
ALOX15 P16050 1/20 0.57
HTT P42858 1/20 0.57
HSD17B10 Q99714 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11895247 1.00 MAPT (0.60) MAPTTP53RXFP1ALDH1A1KDM4E
SCHEMBL11955705 0.85 MAPT (0.50) MAPTTP53RXFP1ALDH1A1KDM4E
SCHEMBL6885965 0.74 MAPT (1.00) MAPTTP53RXFP1ALDH1A1KDM4E
SCHEMBL6887342 0.72 MAPT (0.67) MAPTTP53RXFP1ALDH1A1KDM4E
SCHEMBL12797289 0.68 MAPT (0.85) MAPTTP53RXFP1ALDH1A1KDM4E
SCHEMBL11896072 0.67 MAPT (0.74) MAPTTP53RXFP1ALDH1A1KDM4E
SCHEMBL1815237 0.65 ADORA1 (0.97) MAPTTP53ALDH1A1KDM4EMPI
SCHEMBL12204688 0.64 MAPT (0.67) MAPTTP53RXFP1ALDH1A1KDM4E
SCHEMBL1694638 0.64 DYRK1A (0.49) MAPTTP53RXFP1ALDH1A1KDM4E
Bromide SCHEMBL2762927 0.64 ADORA1 (0.95) MAPTTP53ALDH1A1KDM4EMPI

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10472315-B2 Inhibitors of methionine aminopeptidases and methods of treating disorders THE JOHNS HOPKINS UNIVERSITY (US) 2019-11-12 US disclosed
US-10472315-B2 Inhibitors of methionine aminopeptidases and methods of treating disorders THE JOHNS HOPKINS UNIVERSITY (US) 2019-11-12 US disclosed
US-20120196852-A1 INHIBITORS OF METHIONINE AMINOPEPTIDASES AND METHODS OF TREATING DISORDERS THE JOHNS HOPKINS UNIVERSITY (US) 2012-08-02 US disclosed
US-20120196852-A1 INHIBITORS OF METHIONINE AMINOPEPTIDASES AND METHODS OF TREATING DISORDERS THE JOHNS HOPKINS UNIVERSITY (US) 2012-08-02 US disclosed
WO-2011017519-A2 INHIBITORS OF METHIONINE AMINOPEPTIDASES AND METHODS OF TREATING DISORDERS THE JOHNS HOPKINS UNIVERSITY (US) 2011-02-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120196852-A1 INHIBITORS OF METHIONINE AMINOPEPTIDASES AND METHODS OF TREATING DISORDERS METAP1, METAP2, ENPEP MAPT 1551/4885TP53 2574/4885RXFP1 4351/4885
US-10472315-B2 Inhibitors of methionine aminopeptidases and methods of treating disorders METAP1, METAP2, ENPEP MAPT 1551/4885TP53 2574/4885RXFP1 4351/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.